These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29490219)

  • 21. Learning From Major Clinical Trials: Bending Without Breaking.
    Pfeffer MA
    Circulation; 2017 Dec; 136(23):2207-2209. PubMed ID: 29203564
    [No Abstract]   [Full Text] [Related]  

  • 22. Putting the record straight: granisetron's efficacy as an antiemetic 'post-Fujii'.
    Kranke P
    Anaesthesia; 2012 Oct; 67(10):1063-7. PubMed ID: 22897144
    [No Abstract]   [Full Text] [Related]  

  • 23. Covariate adjustment for randomized controlled trials revisited.
    Wang J
    Pharm Stat; 2020 May; 19(3):255-261. PubMed ID: 31863636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 25. Multi-period crossover trials.
    Matthews JN
    Stat Methods Med Res; 1994 Dec; 3(4):383-405. PubMed ID: 7889228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials methodology: randomization, intent-to-treat, and random-effects regression.
    Atkins DC
    Depress Anxiety; 2009; 26(8):697-700. PubMed ID: 19658122
    [No Abstract]   [Full Text] [Related]  

  • 27. Getting maximum information out of a continuous outcome: applying linear regression.
    de Ridder MA; de Vries T; Arends LR
    EuroIntervention; 2015 Oct; 11(6):718-22. PubMed ID: 26499224
    [No Abstract]   [Full Text] [Related]  

  • 28. Alternatives to Randomised Controlled Trials for the Poor, the Impatient, and When Evaluating Emerging Technologies.
    Mani K; Björck M
    Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):598-599. PubMed ID: 30509892
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Missing data in rheumatologic studies and the practical reality of modern approaches to the analysis of incomplete subject data: comment on the article by Baron et al and the editorial by Boers.
    Steele R; Hudson M
    Arthritis Rheum; 2008 Sep; 59(9):1367-8. PubMed ID: 18759312
    [No Abstract]   [Full Text] [Related]  

  • 31. A note on sequential monitoring of select-the-winner design.
    Lan KK; Chen F; Zhong B; Shun Z
    J Biopharm Stat; 2015; 25(3):408-16. PubMed ID: 25645054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized clinical trial: myths around elementary statistical principles.
    Edler L; Kopp-Schneider A
    Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-hoc data analysis: benefits and limitations.
    Curran-Everett D; Milgrom H
    Curr Opin Allergy Clin Immunol; 2013 Jun; 13(3):223-4. PubMed ID: 23571411
    [No Abstract]   [Full Text] [Related]  

  • 34. Statistics notes: missing outcomes in randomised trials.
    Vickers AJ; Altman DG
    BMJ; 2013 Jun; 346():f3438. PubMed ID: 23744649
    [No Abstract]   [Full Text] [Related]  

  • 35. Adaptive designs from the viewpoint of an academic biostatistician.
    Schäfer H
    Biom J; 2006 Aug; 48(4):586-90; discussion 613-22. PubMed ID: 16972709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

  • 37. Quasi-experimental study designs series-paper 7: assessing the assumptions.
    Bärnighausen T; Oldenburg C; Tugwell P; Bommer C; Ebert C; Barreto M; Djimeu E; Haber N; Waddington H; Rockers P; Sianesi B; Bor J; Fink G; Valentine J; Tanner J; Stanley T; Sierra E; Tchetgen ET; Atun R; Vollmer S
    J Clin Epidemiol; 2017 Sep; 89():53-66. PubMed ID: 28365306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generated effect modifiers (GEM's) in randomized clinical trials.
    Petkova E; Tarpey T; Su Z; Ogden RT
    Biostatistics; 2017 Jan; 18(1):105-118. PubMed ID: 27465235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of randomized controlled trials.
    Peduzzi P; Henderson W; Hartigan P; Lavori P
    Epidemiol Rev; 2002; 24(1):26-38. PubMed ID: 12119853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.